CoChat

CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Open access
Sotaniemi, EA, Rautio, A, Backstrom, M, Arvela, P, Pelkonen, O · 1995 · British Journal of Clinical Pharmacology
Cited by 74

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

1. The in vitro hepatic metabolism of lignocaine to monoethylglycinexylide (MEGX) is mediated by CYP3A4 and that of coumarin to 7‐hydroxycoumarin (7OHC) by CYP2A6. We investigated the usefulness of monitoring serum MEGX concentrations (after 1 mg kg‐1 lignocaine i.v.) and urinary 7OHC excretion (after 5 mg coumarin p.o.) to reflect liver function in patients with liver (n = 36), kidney (n = 12) and epileptic (n = 12) disease and in control subjects (n = 20). The extent of liver disease was assessed using measurements of serum aminoterminal propeptide (PIIINP) and Child‐Pugh grades. 2. Serum concentrations of MEGX were decreased in severe (4.6 +/‐ 3.0 s.d. ng ml‐ 1), moderate (19.1 +/‐ 11.6 s.d. ng ml‐1) and mild (32.8 +/‐ 14.2 s.d ng ml‐1) liver disease as compared with controls (53.4 +/‐ 15.8 s.d ng ml‐1). The excretion of 7OHC over 2 h was decreased in severe (18.0 +/‐ 10.3 s.d % of dose) and moderate (34.2 +/‐ 15.6 s.d %), but not in mild (49.7 +/‐ 19.0 s.d %) liver disease as compared with that in controls (56.2 +/‐ 11.6%). 3. In epileptic patients the urinary recovery of 7OHC was increased (2 h value 69.5 +/‐ 13.2 s.d %) suggesting enzyme induction. In contrast, serum MEGX concentration were low (40.0 +/‐ 14.1 s.d ng ml‐1), possibly due to competition for CYP3A4 between lignocaine and antiepileptic drugs. 4. In patients with kidney disease serum MEGX concentration (56.5 +/‐ 26.1 s.d ng ml‐1) was similar to that in controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1995.tb04412.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 74

Metadata

Authors
Sotaniemi, E., Rautio, A., Backstrom, M., Arvela, P., & Pelkonen, O.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1995-01
Volume
39
Issue
1
Pages
71-76
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1975310291
Cited by
74
References
3
FWCI
2.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. https://app.cochat.ai/papers/10.1111/j.1365-2125.1995.tb04412.x
The paper
Sotaniemi, E., Rautio, A., Backstrom, M., Arvela, P., & Pelkonen, O. (1995). CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1995.tb04412.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.